Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Income from Continuing Operations of 90950000.0 for Q1 2026, down 153.29% year-over-year from 170659576.19 in Q1 2025, and down 175.61% quarter-over-quarter from 32999000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 90950000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 153.29% year-over-year to 90950000.0; the TTM figure through Mar 2026 stood at 199778000.0 (down 28.23% YoY), while the FY2025 annual figure was 144735000.0, up 39.36% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 90950000.0, down from 32999000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 25510000.0 in Q4 2024, with the low at 118793000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 41443000.0 (2025), against an average of 36861117.65.
- Peak annual rise in Income from Continuing Operations reached 845.87% in 2024, while the deepest fall reached 7652.0% in 2024.
- Amylyx Pharmaceuticals' Income from Continuing Operations stood at 43807000.0 in 2022, then jumped by 106.16% to 2697000.0 in 2023, then jumped by 845.87% to 25510000.0 in 2024, then sank by 229.36% to 32999000.0 in 2025, then sank by 175.61% to 90950000.0 in 2026.
- Business Quant data shows AMLX's Income from Continuing Operations at 90950000.0 in Q1 2026, 32999000.0 in Q4 2025, and 34386000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 691.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | -22.50 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 54.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | -121.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -121.94 Mn |
| Mar 31, 2026 | -90.95 Mn |
| Dec 31, 2025 | -33.00 Mn |
| Sep 30, 2025 | -34.39 Mn |
| Jun 30, 2025 | -41.44 Mn |
| Mar 31, 2025 | -35.91 Mn |
| Dec 31, 2024 | 25.51 Mn |
| Sep 30, 2024 | -72.70 Mn |
| Jun 30, 2024 | -72.70 Mn |
| Mar 31, 2024 | -118.79 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 20.89 Mn |
| Jun 30, 2023 | 22.07 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | -43.81 Mn |
| Sep 30, 2022 | -53.76 Mn |
| Jun 30, 2022 | -54.09 Mn |
| Mar 31, 2022 | -47.85 Mn |
| Dec 31, 2021 | -28.32 Mn |
| Sep 30, 2021 | -23.14 Mn |